Abstract
Imatinib is presently the commonest prescribes drug for patients of chronic myelogenous leukemia (CML) in chronic phase (CP) worldwide. Its ocular side effects are little known. Optic neuritis caused by this drug has not been reported (Medline search). We describe perhaps the first case of optic neuritis caused by this drug.
Similar content being viewed by others
References
O’Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994–1004
Kantarjian H, Talpaz M, O’Brien S et al (2004) High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103(8):2873–2878
Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J (2003) Ocular side-effects associated with imatinib mesylate. J Ocul Pharmacol Ther 19(4):371–375
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Govind Babu, K., Attili, V.S.S., Bapsy, P.P. et al. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol 27, 43–44 (2007). https://doi.org/10.1007/s10792-007-9038-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-007-9038-9